US4988815A
(en)
*
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
ES2071340T3
(en)
*
|
1990-10-05 |
1995-06-16 |
Minnesota Mining & Mfg |
PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
|
US5175296A
(en)
*
|
1991-03-01 |
1992-12-29 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
|
US5389640A
(en)
*
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5268376A
(en)
*
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US6608201B2
(en)
*
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5395937A
(en)
*
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
US5622965A
(en)
*
|
1993-03-12 |
1997-04-22 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon |
4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
|
JPH09500128A
(en)
*
|
1993-07-15 |
1997-01-07 |
ミネソタ マイニング アンド マニュファクチャリング カンパニー |
Imidazo [4,5-c] pyridin-4-amine
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5644063A
(en)
*
|
1994-09-08 |
1997-07-01 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]pyridin-4-amine intermediates
|
US5693811A
(en)
*
|
1996-06-21 |
1997-12-02 |
Minnesota Mining And Manufacturing Company |
Process for preparing tetrahdroimidazoquinolinamines
|
US5741908A
(en)
*
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
JP4101302B2
(en)
*
|
1997-01-09 |
2008-06-18 |
テルモ株式会社 |
Novel amide derivatives and synthetic intermediates
|
UA67760C2
(en)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
|
JP2000119271A
(en)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h-imidazopyridine derivative
|
CA2361936C
(en)
|
1999-01-08 |
2009-06-16 |
3M Innovative Properties Company |
Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(en)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
Accelerator device
|
MXPA02007525A
(en)
*
|
2000-02-09 |
2002-12-13 |
Hokuriku Pharmaceutical |
1h imidazopyridine derivatives.
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
WO2006091720A2
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6660747B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6677348B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
UA74852C2
(en)
*
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
JP2005501550A
(en)
*
|
2001-08-30 |
2005-01-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
Maturation of plasmacytoid dendritic cells using immune response modifier molecules
|
DE60230340D1
(en)
*
|
2001-11-16 |
2009-01-22 |
3M Innovative Properties Co |
N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
*
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ES2541132T3
(en)
*
|
2002-02-22 |
2015-07-16 |
Meda Ab |
Method to reduce and treat UV-B-induced immunosuppression
|
WO2003101949A2
(en)
|
2002-05-29 |
2003-12-11 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
MXPA04012199A
(en)
*
|
2002-06-07 |
2005-02-25 |
3M Innovative Properties Co |
Ether substituted imidazopyridines.
|
CN1315828C
(en)
*
|
2002-07-23 |
2007-05-16 |
特瓦药厂私人有限公司 |
Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
|
JP2005537287A
(en)
*
|
2002-07-26 |
2005-12-08 |
テバ ジョジセルジャール レースベニュタールシャシャーグ |
1H-imidazo [4,5-c] quinolin-4-amine with novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinoline-4-carboxamide intermediates Manufacturing
|
EP1545597B1
(en)
|
2002-08-15 |
2010-11-17 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
AU2003299082A1
(en)
*
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003287324A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
WO2004058759A1
(en)
|
2002-12-20 |
2004-07-15 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
CA2511538C
(en)
*
|
2002-12-30 |
2013-11-26 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
US7375180B2
(en)
*
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
Selective modulation of tlr-mediated biological activity
|
CA2517528A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of uv-induced epidermal neoplasia
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
EP1605943A4
(en)
*
|
2003-03-07 |
2008-01-16 |
3M Innovative Properties Co |
1-amino 1h-imidazoquinolines
|
AU2004220465A1
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
CA2518282C
(en)
*
|
2003-03-13 |
2012-11-06 |
3M Innovative Properties Company |
Methods of improving skin quality
|
US7699057B2
(en)
*
|
2003-03-13 |
2010-04-20 |
3M Innovative Properties Company |
Methods for treating skin lesions
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US20040202720A1
(en)
*
|
2003-04-10 |
2004-10-14 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
US20040214851A1
(en)
*
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
AR044466A1
(en)
*
|
2003-06-06 |
2005-09-14 |
3M Innovative Properties Co |
PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
CA2534042A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
CA2534313C
(en)
*
|
2003-08-05 |
2013-03-19 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
TW200510412A
(en)
*
|
2003-08-12 |
2005-03-16 |
3M Innovative Properties Co |
Oxime substituted imidazo-containing compounds
|
CA2535338C
(en)
*
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
US8961477B2
(en)
|
2003-08-25 |
2015-02-24 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
JP2007504145A
(en)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Immunostimulatory combinations and treatments
|
CA2536136C
(en)
*
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
JP2007504172A
(en)
*
|
2003-09-02 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Methods for treatment of mucosa related symptoms
|
JP2007504269A
(en)
*
|
2003-09-05 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Method for treating CD5 + B cell lymphoma
|
EP1664342A4
(en)
*
|
2003-09-17 |
2007-12-26 |
3M Innovative Properties Co |
Selective modulation of tlr gene expression
|
WO2005033049A2
(en)
*
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
|
NZ546274A
(en)
|
2003-10-03 |
2009-12-24 |
3M Innovative Properties Co |
Pyrazolopyridines and analags thereof
|
JP5043435B2
(en)
*
|
2003-10-03 |
2012-10-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
Alkoxy substituted imidazoquinolines
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
AU2004285575A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
ITMI20032121A1
(en)
*
|
2003-11-04 |
2005-05-05 |
Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm |
PROCEDURE FOR THE PREPARATION OF IMIQUIMOD AND ITS INTERMEDIATES
|
CN1906193A
(en)
*
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
Oxime substituted imidazo ring compounds
|
AU2004291122A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
AR046781A1
(en)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS.
|
EP1686992A4
(en)
*
|
2003-11-25 |
2009-11-04 |
3M Innovative Properties Co |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
EP1689361A4
(en)
*
|
2003-12-02 |
2009-06-17 |
3M Innovative Properties Co |
Therapeutic combinations and methods including irm compounds
|
WO2005076783A2
(en)
*
|
2003-12-04 |
2005-08-25 |
3M Innovative Properties Company |
Sulfone substituted imidazo ring ethers
|
WO2005066170A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
CA2552101A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
US20050239735A1
(en)
*
|
2003-12-30 |
2005-10-27 |
3M Innovative Properties Company |
Enhancement of immune responses
|
WO2005066169A2
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
AU2005222995B2
(en)
*
|
2004-03-15 |
2010-08-26 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
WO2005094531A2
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
EP1735010A4
(en)
*
|
2004-04-09 |
2008-08-27 |
3M Innovative Properties Co |
Methods, compositions, and preparations for delivery of immune response modifiers
|
JP2008505857A
(en)
*
|
2004-04-28 |
2008-02-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
Compositions and methods for mucosal vaccination
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
US8017779B2
(en)
*
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006009826A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
EP1765348B1
(en)
|
2004-06-18 |
2016-08-03 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
US7897609B2
(en)
*
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
AU2005282523A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1H imidazo ring systems and methods
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
AU2005282726B2
(en)
*
|
2004-09-02 |
2011-06-02 |
3M Innovative Properties Company |
1-alkoxy 1H-imidazo ring systems and methods
|
JP2008515928A
(en)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Adjuvants for DNA vaccines
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
JP2008526765A
(en)
*
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Treatment of skin metastases
|
WO2006074003A2
(en)
*
|
2004-12-30 |
2006-07-13 |
3M Innovative Properties Company |
CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
|
US8034938B2
(en)
|
2004-12-30 |
2011-10-11 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
CA2592897A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Takeda Pharmaceutical Company Limited |
1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
|
WO2006084251A2
(en)
*
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
AU2006212765B2
(en)
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
AU2006338521A1
(en)
|
2005-02-09 |
2007-10-11 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
|
JP2008530113A
(en)
|
2005-02-11 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods
|
CA2597446A1
(en)
*
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
EP1858920B1
(en)
|
2005-02-18 |
2016-02-03 |
GlaxoSmithKline Biologicals SA |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
SG164344A1
(en)
|
2005-02-18 |
2010-09-29 |
Novartis Vaccines & Diagnostics Srl |
Immunogens from uropathogenic escherichia coli
|
JP2008531567A
(en)
*
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
Hydroxyalkyl-substituted imidazoquinoline compounds and methods
|
US8178677B2
(en)
*
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
AU2006216799A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
AU2006216686A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
MX2007011112A
(en)
*
|
2005-03-14 |
2007-11-07 |
Graceway Pharmaceuticals Llc |
Method of treating actinic keratosis.
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
US7943610B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
JP2008539252A
(en)
*
|
2005-04-25 |
2008-11-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
Immune activation composition
|
EA200800782A1
(en)
*
|
2005-09-09 |
2008-08-29 |
Коли Фармасьютикал Груп, Инк. |
AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US7629027B2
(en)
*
|
2005-10-14 |
2009-12-08 |
3M Innovative Properties Company |
Method for making chromonic nanoparticles
|
US7718716B2
(en)
*
|
2005-10-14 |
2010-05-18 |
3M Innovative Properties Company |
Chromonic nanoparticles containing bioactive compounds
|
PT1951299E
(en)
|
2005-11-04 |
2012-02-28 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
EP1945252B1
(en)
|
2005-11-04 |
2013-05-29 |
Novartis Vaccines and Diagnostics S.r.l. |
Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
|
CA2628206A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
JP5247458B2
(en)
|
2005-11-04 |
2013-07-24 |
スリーエム・イノベイティブ・プロパティーズ・カンパニー |
Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
|
JP2009514839A
(en)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Adjuvant influenza vaccine containing cytokine inducer
|
US20070128291A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Tokie Jeffrey H |
Method and Apparatus for Forming Chromonic Nanoparticles
|
US7807661B2
(en)
*
|
2005-12-08 |
2010-10-05 |
3M Innovative Properties Company |
Silver ion releasing articles and methods of manufacture
|
US7323568B2
(en)
*
|
2005-12-12 |
2008-01-29 |
Chemagis Ltd. |
Process for preparing Imiquimod
|
JP6087041B2
(en)
|
2006-01-27 |
2017-03-08 |
ノバルティス アーゲー |
Influenza virus vaccine containing hemagglutinin and matrix protein
|
WO2007100634A2
(en)
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
WO2007106854A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
EP2382988A1
(en)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Combined mucosal and parenteral immunization against HIV
|
ATE522541T1
(en)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
BACTERIAL ADHESIN CONFORMERS
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
WO2008023333A2
(en)
*
|
2006-08-22 |
2008-02-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
|
US8178539B2
(en)
*
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
ES2536401T3
(en)
|
2006-09-11 |
2015-05-25 |
Novartis Ag |
Making vaccines against influenza viruses without using eggs
|
US20080103310A1
(en)
*
|
2006-10-16 |
2008-05-01 |
Janos Hajko |
Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
|
ES2480491T3
(en)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vaccines including four influenza virus strains antigen
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US7943771B2
(en)
*
|
2007-01-24 |
2011-05-17 |
Chemagis Ltd. |
Imiquimod production process
|
US7659398B2
(en)
*
|
2007-02-14 |
2010-02-09 |
Chemagis Ltd. |
Imiquimod production process
|
BRPI0808272A2
(en)
*
|
2007-03-08 |
2014-07-08 |
Chemagis Ltd |
"METHOD FOR CHROMATOGRAPHICALLY SEPARATING THE 1R-CIS ISOMER, 1´R-CIS FROM A MIXTURE OF (1R-1'R) ISOMERS - ATTRACURIUM, CISATRACURY BESILATE, 1R-CIS ISOLOMUS OF THE CESATRUM "
|
CA2681060A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Chemagis Ltd. |
(1r,1'r)-atracurium salts separation process
|
WO2008132746A1
(en)
*
|
2007-05-01 |
2008-11-06 |
Chemagis Ltd. |
Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates
|
CA2685491A1
(en)
*
|
2007-05-01 |
2008-11-06 |
Chemagis Ltd. |
Process for producing cisatracurium compounds and associated intermediates
|
WO2008155752A1
(en)
*
|
2007-06-18 |
2008-12-24 |
Chemagis Ltd. |
(1r,1'r)-atracurium salts separation process
|
EP2009002A1
(en)
*
|
2007-06-21 |
2008-12-31 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
|
BRPI0813866A2
(en)
|
2007-06-27 |
2015-01-06 |
Novartis Ag |
VACCINES AGAINST INFLUENCE WITH LOW ADDITIVE CONTENT
|
EP2176227A1
(en)
*
|
2007-07-09 |
2010-04-21 |
Chemagis Ltd. |
Process for producing cisatracurium and associated intermediates
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816519A2
(en)
*
|
2007-10-29 |
2015-03-24 |
Chemagis Ltd |
Process for preparing an isomerically enriched r, r'-atracurium salt and r, r'-atracurium salt
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
JP5518041B2
(en)
|
2008-03-18 |
2014-06-11 |
ノバルティス アーゲー |
Improvements in the preparation of influenza virus vaccine antigens
|
AU2009241211A1
(en)
*
|
2008-05-01 |
2009-11-05 |
Chemagis Ltd. |
Cisatracurium derivatives, preparation and uses thereof
|
EP3549602A1
(en)
|
2009-03-06 |
2019-10-09 |
GlaxoSmithKline Biologicals S.A. |
Chlamydia antigens
|
SI2510947T1
(en)
|
2009-04-14 |
2016-05-31 |
Glaxosmithkline Biologicals S.A. |
Compositions for immunising against Staphylococcus aureus
|
KR20120027276A
(en)
|
2009-04-27 |
2012-03-21 |
노파르티스 아게 |
Adjuvanted vaccines for protecting against influenza
|
CA2767536A1
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
BR112012001666A2
(en)
|
2009-07-15 |
2019-09-24 |
Novartis Ag |
rsv f protein compositions and methods for making the same
|
JP2012532626A
(en)
|
2009-07-16 |
2012-12-20 |
ノバルティス アーゲー |
Detoxified Escherichia coli immunogen
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
ES2707778T3
(en)
|
2009-12-30 |
2019-04-05 |
Glaxosmithkline Biologicals Sa |
Immunogens polysaccharides conjugated with carrier proteins of E. coli
|
PT2575873E
(en)
|
2010-06-01 |
2016-03-04 |
Novartis Ag |
Concentration and lyophilization of influenza vaccine antigens
|
ES2825712T3
(en)
|
2010-06-01 |
2021-05-17 |
Seqirus Uk Ltd |
Influenza Vaccine Antigen Concentration Without Freeze Drying
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
HUE033901T2
(en)
|
2010-08-17 |
2018-01-29 |
3M Innovative Properties Co |
Lipidated immune response modifier compound compositions, formulations, and methods
|
ES2531577T3
(en)
|
2010-08-20 |
2015-03-17 |
Novartis Ag |
Needle sets for administration of soluble flu vaccine
|
SI2667892T1
(en)
|
2011-01-26 |
2019-05-31 |
Glaxosmithkline Biologicals Sa |
Rsv immunization regimen
|
ES2651143T3
(en)
|
2011-05-13 |
2018-01-24 |
Glaxosmithkline Biologicals Sa |
RS prefusion F antigens
|
JP6460789B2
(en)
|
2011-06-03 |
2019-01-30 |
スリーエム イノベイティブ プロパティズ カンパニー |
Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker
|
BR112013031039B1
(en)
|
2011-06-03 |
2020-04-28 |
3M Innovative Properties Co |
hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
CN104080479B
(en)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
Carrier molecules including spr0096 and spr2021 antigen
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
DK2844282T3
(en)
|
2012-05-04 |
2019-07-15 |
Pfizer |
PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES
|
WO2014053521A2
(en)
|
2012-10-02 |
2014-04-10 |
Novartis Ag |
Nonlinear saccharide conjugates
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
ES2769647T3
(en)
|
2014-03-26 |
2020-06-26 |
Glaxosmithkline Biologicals Sa |
Mutant Staphylococcal Antigens
|
EP3728255B1
(en)
|
2017-12-20 |
2022-01-26 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
FR3113287B1
(en)
|
2020-08-07 |
2023-06-23 |
Phv Pharma |
Industrial process for the synthesis of imiquimod from quinoline-2,4-diol applicable to its pharmaceutical use
|